Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05027425 · ClinicalTrials.gov registry record · Phase 2
Durvalumab (MEDI4736) and Tremelimumab for Hepatocellular Carcinoma in Patients Listed for a Liver Transplant
A Phase 2 study of Hepatocellular Carcinoma and Cirrhosis, sponsored by Davendra Sohal.
- Active
- Registry status
- Phase 2
- Development phase
- 30
- Enrollment target
- 3
- Study locations
NCT05027425 is a Phase 2 study of Hepatocellular Carcinoma and Cirrhosis that is active but no longer recruiting, run by Davendra Sohal. The registered enrollment target is 30 participants, below the 257-participant average among 145 other Hepatocellular Carcinoma trials with a reported enrollment target (88% lower). The trial reports 3 study locations across 3 states.
The verdict
NCT05027425, a Phase 2 study of Hepatocellular Carcinoma and Cirrhosis, is active but no longer recruiting, sponsored by Davendra Sohal.
- ACTIVE NOT RECRUITING
- Registry status
- Phase 2
- Development phase
- 30 participants
- Enrollment target
- 3
- Study locations
Study Summary
Immunotherapy can safely downstage patients and achieve durable systemic disease control to improve clinical outcomes in HCC patients undergoing liver transplant.
Conditions Studied
Interventions
- DRUG Durvalumab
- DRUG Tremelimumab
- PROCEDURE Liver Transplant
Study Locations (3)
Missouri
- Washington University School of Medicine - St Louis
Ohio
- University of Cincinnati - Cincinnati
Texas
- Simmons Comprehensive Cancer Center UT Southwestern Medical Center - Dallas
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 30 participants |
| Start Date | 2021-12-07 |
| Est. Completion | 2030-12-07 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05027425
The ClinicalTrials.gov registry entry for NCT05027425 describes a study currently listed as active not recruiting, categorized as Phase 2. The registered enrollment target is 30 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 257-participant average among 145 other Hepatocellular Carcinoma trials with a reported enrollment target (88% lower). The listed sponsor is Davendra Sohal, which has 1 total studies on file at ClinicalTrials.gov.
The record links to 3 conditions, with Hepatocellular Carcinoma appearing as the primary indexed condition, and to 3 interventions - of which Durvalumab is the first listed.
NCT05027425 reports 3 study locations spanning 3 distinct geographic areas - top geographies include Missouri, Ohio, Texas.
Frequently Asked Questions
What is clinical trial NCT05027425 about?
NCT05027425 is a clinical study titled "Durvalumab (MEDI4736) and Tremelimumab for Hepatocellular Carcinoma in Patients Listed for a Liver Transplant". Immunotherapy can safely downstage patients and achieve durable systemic disease control to improve clinical outcomes in HCC patients undergoing liver transplant.
What is the current status of trial NCT05027425?
This trial is currently active not recruiting. It is a Phase 2 study. The enrollment target is 30 participants. The study started on 2021-12-07. Estimated completion is 2030-12-07.
What conditions does trial NCT05027425 study?
This clinical trial studies the following conditions: Hepatocellular Carcinoma, Cirrhosis, Portal Hypertension.
What interventions are being tested in trial NCT05027425?
The interventions under investigation include: Durvalumab (DRUG), Tremelimumab (DRUG), Liver Transplant (PROCEDURE).
Who is sponsoring clinical trial NCT05027425?
This trial is sponsored by Davendra Sohal, which has 1 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05027425 being conducted?
This trial has 3 study locations across Missouri, Ohio, Texas. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Hepatocellular Carcinoma
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Anti-PD-1 mAb Plus Metabolic Modulator in Solid Tumor Malignancies
RECRUITING · Phase 2
-
Combination of TATE and PD-1 Inhibitor in Liver Cancer
RECRUITING · Phase 2
-
Zanzalintinib (XL-092) Plus Durvalumab and Tremelimumab in Unresectable Hepatocellular Carcinoma (ZENOBIA)
RECRUITING · Phase 2
-
Regorafenib and Yttrium-90 Radioembolization for Unresectable Hepatocellular Carcinoma
RECRUITING · Phase 2
-
A Prospective Study of Memantine in Patients With Cirrhosis and Liver Cancer
RECRUITING · Phase 2
-
A Study Evaluating Atezolizumab, With or Without Bevacizumab, in Participants With Unresectable Hepatocellular Carcinoma and Child-pugh B7 and B8 Cirrhosis
RECRUITING · Phase 2
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.